Search

Press Release: “Building the knowledge economy in the world of blood diseases: patients, professionals and Parliamentarians help make the new Europe.”

Aug 30 2011 Posted in Advocacy news

Brussels, 29th August 2011

On the 30th & 31st of August a conference will be hosted in the European Parliament that will demonstrate the leading role haematology will have in securing the future knowledge economy envisaged in the Europe 2020 Strategy.…

CRTH – reflections on a unique learning experience

Mar 11 2021

CRTH (Clinical Research Training in Hematology) is a 9-month long unique training and mentoring experience focused on clinical research in Europe, with a global scope.

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

Dec 13 2023

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition

Nov 18 2020

PRESS RELEASE
Strategic Partnership: EBMT and EHA aim to position Europe in the lead of the global cellular therapy field with the new GoCART coalition

The Hague, Wednesday 18, November, 2020

The field of cell and gene therapy is one of the most…

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

Jun 14 2013

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Press Release: News on Red Cells and Iron presented at the 18th Congress of the European Hematology Asscociation in Stockholm June 13-16, 2013

Jun 10 2013 Posted in Press releases

Recent evidence suggests that these congenital anaemias are caused by molecular abnormalities in the transport of iron and other molecules and a deeper understanding of these mechanisms may lead to a better knowledge of the normal development of the red…

Evidence and policy to ensure good clinical practice

Jan 06 2020

Interview with Vinay Prasad MD MPH by Heiko Becker MD, on behalf of YoungEHA

Leaders in the field that have the potential to make a difference, that challenge the way we are doing things, who push our perspective out of our…

EHA-SWG Scientific Meeting on From Aging Hematopoietic Stem Cells to Age-related Diseases: Opportunities for Intervention

Dates: November 13-15, 2025
Location: Barcelona, Spain
Chairs: M Essers, E Laurenti, S Valletta, K Kirschner
Collaborating SWG: EHA Specialized Working Group (SWG) on Stem Cells and SWG on Aging

Registration will be open soon

Join leading experts in hematopoietic stem cell (HSC) biology and aging, and…

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

Mar 28 2013 Posted in Press releases

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.

Report on first EHA-SWG Scientific Meeting

Jan 16 2013

The meeting was organized with the main support of the EHA in collaboration with the Hematology Unit of G. Gaslini Children’s Hospital and was sponsored by Novartis and Alexion.